Paraneoplastic neurologic syndromes

Neurologic Clinics

Volumn 21, Issue 1, 2003, Pages 221-247

  Bataller, Luis ^a   Dalmau, Josep ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING DISORDER; CENTRAL NERVOUS SYSTEM INFECTION; DIAGNOSTIC APPROACH ROUTE; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; METABOLIC DISORDER; METASTASIS; NUTRITIONAL DEFICIENCY; PARANEOPLASTIC NEUROPATHY; PRIORITY JOURNAL; REVIEW; TUMOR DIAGNOSIS;

BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; HUMANS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 0037309798     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(02)00037-3     Document Type: Review

References (152)

1. Dalmau JO, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 1997;24:318-28.
2. Elrington GM, Murray NM, Spiro SG, et al. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991;54:764-7.
3. Namba T, Brunner NG, Grob D. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine (Baltimore) 1978;57:411-33.
4. van Oosterhout AGM, van de Pol M, ten Velde GPM, et al. Neurologic disorders in 203 consecutive patients with small cell lung cancer - results of a longitudinal study. Cancer 1996;77:1434-41.
5. Paul T, Katiyar BC, Misra S, et al. Carcinomatous neuromuscular syndromes. A clinical and quantitative electrophysiological study. Brain 1978;101:53-63.
6. Trojaborg W, Frantzen E, Andersen I. Peripheral neuropathy and myopathy associated with carcinoma of the lung. Brain 1969;92:71-82.
7. Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999;9:275-84.
8. Graus F, Dalmau J, Reñé R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997;15:2866-72.
9. Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999;353:117-8.
10. Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 11:1321-4.
11. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000;55:713-5.
12. Forsyth PA, Dalmau J, Graus F, et al. Motor neuron syndromes in cancer patients. Ann Neurol 1997;41:722-30.
13. Wanschitz J, Hainfellner JA, Kristoferitsch W, et al. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology 1997;49:1156-9.
14. Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998;51:1146-50.
15. Benyahia B, Liblau R, Merle-Béral H, et al. Cell-mediated auto-immunity in paraneoplastic neurologic syndromes with anti-Hu antibodies. Ann Neurol 1999;45:162-7.
16. Tanaka M, Tanaka K, Shinozawa K, et al. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1998;161:88-90.
17. Tanaka K, Tanaka M, Inuzuka T, et al. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurol Sci 1999;163:159-62.
18. Keime-Guibert F, Graus F, Broet P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999;53:1719-23.
19. Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001;50:339-48.
20. Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of antineural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416-24.
21. Oh SJ. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin 1997; 15:849-63.
22. Antoine JC, Cinotti L, Tilikete C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000;48:105-8.
23. Rees JH, Hain SF, Johnson MR, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001;124:2223-31.
24. Kelly JJ Jr. Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve 1985;8:138-50.
25. Buckley C, Newsom-Davis J, Willcox N, et al. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001;57:1579-82.
26. Antoine JC, Honnorat J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001;49:214-21.
27. Molinuevo JL, Graus F, Reñé R, et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998;44:976-80.
28. Dalmau J, Furneaux HM, Gralla RJ, et al. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - a quantitative western blot analysis. Ann Neurol 1990;27:544-52.
29. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-54.
30. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481-94.
31. Stubgen JP. Nervous system lupus mimics limbic encephalitis. Lupus 1998;7:557-60.
32. Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol 2001;50:612-9.
33. Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain 1965;88:449-64.
34. Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999;45:255-8.
35. Dalmau J, Graus F, Rosenblum MK, et al. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992;71:59-72.
36. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997;120:1279-300.
37. Graus F, Keime-Guibert F, Reñé R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-48.
38. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-7.
39. Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931-7.
40. Henson RA, Urich HE. Cancer and the nervous system: the neurological manifestations of systemic malignant disease. London (UK): Blackwell Scientific; 1982.
41. Giometto B, Marchiori GC, Nicolao P, et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 1997;23:468-74.
42. Verschuuren J, Chuang L, Rosenblum MK, et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol 1996;91:519-25.
43. Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998;96:1-7.
44. Uchuya M, Graus F, Vega F, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996;60:388-92.
45. Leigh RJ, Zee DSE. Diagnosis of central disorders of ocular motility. The neurology of eye movements. Philadelphia: FA Davis Co; 1983. p. 191-262.
46. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001;124:437-43.
47. Hormigo A, Dalmau J, Rosenblum MK, et al. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol 1994;36:896-902.
48. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991;29:241-51.
49. Koh PS, Raffensperger JG, Berry S, et al. Long-term outcome in children with opsoclonusmyoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994;125:712-6.
50. Russo C, Cohn SL, Petruzzi MJ, et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997;28:284-8.
51. Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002;109:86-98.
52. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies - a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001;36:612-22.
53. Rowland LP, Schneck SA. Neuromuscular disorders associated with malignant neoplastic disease. J Chron Dis 1963;16:777-95.
54. Brouqui P, Bollet C, Delmont J, et al. Diagnosis of progressive multifocal leucoencephalopathy by PCR detection of JC virus from CSF. Lancet 1992;339:1182.
55. Iwamasa T, Utsumi Y, Sakuda H, et al. Two cases of necrotizing myelopathy associated with malignancy caused by herpes simplex virus type 2. Acta Neuropathol 1989;78:252-7.
56. Wiley CA, VanPatten PD, Carpenter PM, et al. Acute ascending necrotizing myelopathy caused by herpes simplex virus type 2. Neurology 1987;37:1791-4.
57. Rosenfeld MR, Posner JB. Paraneoplastic motor neuron disease. Adv Neurol 1991;56:445-59.
58. Evans BK, Fagan C, Arnold T, et al. Paraneoplastic motor neuron disease and renal cell carcinoma: improvement after nephrectomy. Neurology 1990;40:960-2.
59. Younger DS, Rowland LP, Latov N, et al. Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol 1991;29:78-86.
60. Younger DS, Rowland LP, Latov N, et al. Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology 1990;40:595-9.
61. Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. Mayo Clin Proc 1989;64:629-36.
62. Moersch F, Woltman H. Progressive fluctuating muscular rigidity and spasm ("stiffman syndrome"): report of a case and some observations in 13 other cases. Mayo Clin Proc 1956;31:421-2.
63. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000;26:307-12.
64. Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993;328:546-51.
65. Solimena M, Folli F, Aparisi R, et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990;322:1555-60.
66. Saiz A, Minguez A, Graus F, et al. Stiff-man syndrome with vacuolar degeneration of anterior horn motor neurons. J Neurol 1999;246:858-60.
67. Chalk CH, Windebank AJ, Kimmel DW, et al. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 1992;19:346-51.
68. Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002;125:166-75.
69. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997;20:1576-82.
70. Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer. Philadelphia: F.A. Davis; 1995. p. 282-310.
71. Antoine JC, Mosnier JF, Absi L, et al. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999;67:7-14.
72. Vincent D, Dubas F, Hauw JJ, et al. Nerve and muscle microvasculitis in peripheral neuropathy: a remote effect of cancer? J Neurol Neurosurg Psychiatry 1986;49:1007-10.
73. Kelly JJ Jr, Kyle RA, O'Brien PC, et al. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981;31:1480-3.
74. Walsh JC. The neuropathy of multiple myeloma. An electrophysiological and histological study. Arch Neurol 1971;25:404-14.
75. Kelly JJ Jr, Kyle RA, Miles JM, et al. Osteosclerotic myeloma and peripheral neuropathy. Neurology 1983;33:202-10.
76. Iwashita H, Ohnishi A, Asada M, et al. Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma. Neurology 1977;27:675-81.
77. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984;34:712-20.
78. Gherardi RK, Belec L, Soubrier M, et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996;87:1458-65.
79. Davis LE, Drachman DB. Myeloma neuropathy. Successful treatment of two patients and review of cases. Arch Neurol 1972;27:507-11.
80. Ponsford S, Willison H, Veitch J, et al. Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy. Muscle Nerve 2000;23:164-74.
81. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000;18:214.
82. Kusunoki S, Kohriyama T, Pachner AR, et al. Neuropathy and IgM paraproteinemia: differential binding of IgM M- proteins to peripheral nerve glycolipids. Neurology 1987;37:1795-7.
83. Chassande B, Leger JM, Younes-Chennoufi AB, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998;21:55-62.
84. Vital C, Vallat JM, Deminiere C, et al. Peripheral nerve damage during multiple myeloma and Waldenstrom's macroglobulinemia: an ultrastructural and immunopathologic study. Cancer 1982;50:1491-7.
85. Dalakas MC, Flaum MA, Rick M, et al. Treatment of polyneuropathy in Waldenstrom's macroglobulinemia: role of paraproteinemia and immunologic studies. Neurology 1983;33:1406-10.
86. Latov N. Prognosis of neuropathy with monoclonal gammopathy. Muscle Nerve 2000;23:150-2.
87. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999;52:1701-4.
88. Oksenhendler E, Chevret S, Leger JM, et al. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1995;59:243-7.
89. Wilson HC, Lunn MP, Schey S, et al. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999;66:575-80.
90. Vallat JM, De Mascarel HA, Bordessoule D, et al. Non-Hodgkin malignant lymphomas and peripheral neuropathies-13 cases. Brain 1995;118:1233-45.
91. Ku A, Lachmann E, Tunkel R, et al. Severe polyneuropathy: initial manifestation of Castleman's disease associated with POEMS syndrome. Arch Phys Med Rehabil 1995;76:692-4.
92. Vingerhoets F, Kuntzer T, Delacretaz F, et al. Chronic relapsing neuropathy associated with Castleman's disease (angiofollicular lymph node hyperplasia). Eur Neurol 1995;35:336-40.
93. Donaghy M, Hall P, Gawler J, et al. Peripheral neuropathy associated with Castleman's disease. J Neurol Sci 1989;89:253-67.
94. Belec L, Mohamed AS, Authier FJ, et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 1999;93:3643-53.
95. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
96. Jiang GX, Cheng Q, Link H, et al. Epidemiological features of Guillain-Barre syndrome in Sweden, 1978-93. J Neurol Neurosurg Psychiatry 1997;62:447-53.
97. Sridharan GV, Tallis RC, Gautam PC. Guillain-Barre syndrome in the elderly. A retrospective comparative study. Gerontology 1993;39:170-5.
98. Lisak RP, Mitchell M, Zweiman B, et al. Guillain-Barre syndrome and Hodgkin's disease: Three cases with immunological studies. Ann Neurol 1977;1:72-8.
99. McKhann GM, Griffin JW, Cornblath DR, et al. Role of therapeutic plasmapheresis in the acute Guillain-Barre syndrome. J Neuroimmunol 1988;20:297-300.
100. Van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992;326:1123-9.
101. Pezzimenti JF, Bruckner HW, DeConti RC. Paralytic brachial neuritis in Hodgkin's disease. Cancer 1973;31:626-32.
102. Lachance DH, O'Neill BP, Harper CM Jr, et al. Paraneoplastic brachial plexopathy in a patient with Hodgkin's disease. Mayo Clin Proc 1991;66:97-101.
103. Isaacs H. A syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry 1961;24:319-25.
104. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaac's syndrome). Report of five cases and literature review. Brain 1993;116:453-69.
105. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995;38:714-22.
106. Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50:73-8.
107. Evoli A, Lo MM, Marra R, et al. Multiple paraneoplastic diseases associated with thymoma. Neuromuscul Disord 1999;9:601-3.
108. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-96.
109. Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clinic Proc 1968;43:689-713.
110. O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 1998;50:88-93.
111. Eaton LM, Lambert EH. Electromyography and electrical stimulation of nerves in diseases of the motor unit: observations on a myasthenic syndrome associated with malignant tumors. JAMA 1957;163:1117-24.
112. Jablecki C. Lambert-Eaton myasthenic syndrome. Muscle Nerve 1984;7:250-7.
113. Sanders DB. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995;37:63-73.
114. Lang B, Newsom-Davis J, Peers C, et al. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol 1987;390:257-70.
115. Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981;2:224-6.
116. Motomura M, Lang B, Johnston I, et al. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35-42.
117. Gutmann L, Phillips LH, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology 1992;42:848-50.
118. Newsom-Davis J. A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998;841:817-22.
119. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-83.
120. Rich MM, Teener JW, Bird SJ. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 1997;20:614-5.
121. Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann N Y Acad Sci 1998;841:811-6.
122. Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603-7.
123. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci 1998;841:823-6.
124. Oh SJ, Kim DS, Kwon KH, et al. Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998;841:827-31.
125. Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982;11:570-5.
126. Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40:1552-6.
127. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-810.
128. Drachman DB, Angus CW, Adams RN, et al. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978;298:1116-22.
129. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8.
130. Mineo TC, Biancari F, D'Andrea V. Late onset of myasthenia gravis after total resection of thymoma: report of two cases. J Cardiovasc Surg 1996;37:531-3.
131. Lambert EH, Rooke ED. Myasthenic state and lung cancer. In: Brain L, Norris FH Jr, editors. The remote effects of cancer on the nervous system. New York: Grune and Stratton; 1965. p. 67-80.
132. Papatestas AE, Osserman KE, Kark AE. The relationship between thymus and oncogenesis. A study of the incidence of non thymic malignancy in myasthenia gravis. Br J Cancer 1971;25:635-45.
133. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325:1487-98.
134. Horowitz M, McNeil JD, Maddern GJ, et al. Abnormalities of gastric and esophageal emptying in polymyositis and dermatomyositis. Gastroenterology 1986;90:434-9.
135. Lam WW, Chan H, Chan YL, et al. MR imaging in amyopathic dermatomyositis. Acta Radiol 1999;40:69-72.
136. Osman Y, Narita M, Kishi K, et al. Case Report: amyopathic dermatomyositis associated with transformed malignant lymphoma. Am J Med Sci 1996;311:240-2.
137. Askari AD, Huettner TL. Cardiac abnormalities in polymyositis/dermatomyositis. Sem Arth Rheum 1982;12:208-19.
138. Lakhanpal S, Lie JT, Conn DL, et al. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1987;46:23-9.
139. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 1994. p. 1335-83.
140. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329-34.
141. Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med 1972;286:333-8.
142. Gallais V, Crickx B, Belaich S. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 1996;123:722-6.
143. Hochberg MC, Feldman D, Stevens MB, et al. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 1984;11:663-5.
144. Sigurgeirsson B, Lindelof B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-7.
145. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
146. Tahri A, Jouhadi H, Fadil H, et al. Polymyositis in a patient with fallopian tube cancer. J Gynecol Obstet Biol Reprod (Paris) 2001;30:601-3.
147. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615-48.
148. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
149. Levin MI, Mozaffar T, Al Lozi MT, et al. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998;50:764-7.
150. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991;41:936-9.
151. Anderlini P, Buzaid AC, Legha SS. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma. Cancer 1995;76:678-9.
152. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve and muscle. Muscle Nerve 2000;23:1800-18.